About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
G.D. Searle LLC et al. v. Lupin Pharmaceuticals, Inc. et al.
2:13-cv-00121; filed March 5, 2013 in the Eastern District of Virginia
• Plaintiffs: G.D. Searle LLC; Pfizer Asia Pacific PTE, LTD.;
• Defendants: Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Watson Laboratories, Inc.; Apotex Inc.; Apotex Corp.
Infringement of U.S. Patent No. RE44,048 ("4-[5-(4-Methylphenyl)-3-(Trifluoromethyl)-1H-Pyrazol-1-yl]Benzenesulfonamide for the Treatment of Inflammation or an Inflammation-Associated Disorder," reissued march 5, 2013) in conjunction with defendants' filing of an ANDA to manufacture a generic version of Pfizer's Celebrex® (celecoxib, used to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea). View the complaint here.
AbbVie Inc. et al. v. The Kennedy Trust Rheumatology Research
1:13-cv-01358; filed February 28, 2013 in the Southern District of New York
• Plaintiffs: AbbVie Inc.; AbbVie Biotechnology Limited
• Defendant: The Kennedy Trust Rheumatology Research
Declaratory judgment of invalidity of U.S. Patent Nos. 8,298,537 ("Concomitant Treatment of Rheumatoid Arthritis with Anti-TNF-a Antibodies and Methotrexate," issued October 30, 2012) and 8,383,120 (same title, issued February 26, 2013) in conjunction with Abbott's manufacture and sale of its Humira® (adalimumab, used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis). View the complaint here.
